All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
Association between molecular profile and outcomes in secondary or adverse cytogenetic AML: A FILO study
Results from a FILO study, investigating the association between molecular profile and outcome following intensive chemotherapy in older fit patients >60 years with secondary or adverse cytogenetic acute myeloid leukemia (AML) enrolled in the multicenter, prospective Rev5Aza trial (NCT01301820), were published in the American Journal of Hematology. Molecular profiles were available for 97 and 73 patients from the Rev5Aza and the control cohort, respectively.
Key data: Adverse cytogenetics were associated with worse overall survival (OS) than therapy-related acute myeloid leukemia [median OS, 8.28 vs 19.68 months; p < 0.001] in the Rev5Aza cohort. Among patients with adverse cytogenetics, those with complex karyotype (CK) vs other cytogenetic abnormalities (p < 0.001) as well as those with TP53 mutations vs de novo or secondary AML (p < 0.001) had lower OS. The control cohort showed similar outcomes, except that patients with CK, TP53 mutations, or both had comparable OS.
Key learning: The findings suggest that cytogenetic and molecular risk stratification is more predictive of outcomes compared with clinical history in older patients with either secondary or adverse cytogenetic AML.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
When choosing treatment for patients with AML, how much is your selection influenced by your personal experience with a treatment’s safety profile?
